Back
ProShares Ultra MSCI Emerging Markets Vs. Kymera Therapeutics Industry Stock Comparison
Buy
53
EET
ProShares Ultra MSCI Emerging Markets
Last Price:
61.45
Seasonality Move:
7.06%
Buy
71
KYMR
Kymera Therapeutics
Last Price:
46.27
Seasonality Move:
65.72%
Buy
53
ProShares Ultra MSCI Emerging Markets (EET)
is a Buy
Is ProShares Ultra MSCI Emerging Markets a Buy, Sell or Hold?
- The current ProShares Ultra MSCI Emerging Markets [EET] share price is $59.63. The Score for EET is 53, which is 6% above its historic median score of 50, and infers lower risk than normal.
- EET is currently trading in the 50-60% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
Buy
71
Kymera Therapeutics (KYMR)
is a Buy
Is Kymera Therapeutics a Buy, Sell or Hold?
- The current Kymera Therapeutics [KYMR] share price is $49.02. The Score for KYMR is 71, which is 42% above its historic median score of 50, and infers lower risk than normal.
- KYMR is currently trading in the 70-80% percentile range relative to its historical Stock Score levels.
- This Score is currently showing a higher than normal reading, suggesting risk levels may be somewhat lower than normal.
EET Stock Price Chart
What is ProShares Ultra MSCI Emerging Markets's stock price today?
-
The ProShares Ultra MSCI Emerging Markets share price today is $59.63
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and EET is experiencing slight buying pressure.
KYMR Stock Price Chart
What is Kymera Therapeutics's stock price today?
-
The Kymera Therapeutics share price today is $49.02
Based on the share price being above its 5, 20 & 50 day exponential moving averages, the current trend is considered strongly bullish and KYMR is experiencing buying pressure, which is a positive indicator for future bullish movement.
EET Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | 1.23 | Buy |
| Relative Strength Index (14 RSI): | 50.72 | Buy |
| Chaikin Money Flow: | 0 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (55.84 - 62.98) | Buy |
| Bollinger Bands (100): | (52.16 - 58.92) | Buy |
KYMR Technical Analysis
| Chart Indicators | Level | Buy or Sell |
|---|---|---|
| MACD (12, 26): | -0.28 | Sell |
| Relative Strength Index (14 RSI): | 59.12 | Buy |
| Chaikin Money Flow: | 317205 | - |
| Bollinger Bands | Level | Buy or Sell |
|---|---|---|
| Bollinger Bands (25): | (43.81 - 49.49) | Buy |
| Bollinger Bands (100): | (34.86 - 47.92) | Buy |
EET Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 61.2 | Sell |
| 20-day SMA: | 60.81 | Sell |
| 50-day SMA: | 56.64 | Buy |
| 200-day SMA: | 52.97 | Buy |
| 8-day EMA: | 60.69 | Sell |
| 20-day EMA: | 60.06 | Sell |
| 50-day EMA: | 57.78 | Buy |
| 200-day EMA: | 53.95 | Buy |
KYMR Moving Averages
| Moving Averages | Level | Buy or Sell |
|---|---|---|
| 8-day SMA: | 44.58 | Buy |
| 20-day SMA: | 46.67 | Buy |
| 50-day SMA: | 46.11 | Buy |
| 200-day SMA: | 38.62 | Buy |
| 8-day EMA: | 45.67 | Buy |
| 20-day EMA: | 45.85 | Buy |
| 50-day EMA: | 45.2 | Buy |
| 200-day EMA: | 38.5 | Buy |
ProShares Ultra MSCI Emerging Markets Earnings Growth & EET Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.00 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.00 per share, and a decrease next year of $0.00 per share.
Kymera Therapeutics Earnings Growth & KYMR Earnings Dates
- Analysts estimate an earnings decrease this quarter of $0.07 per share, a decrease next quarter of $0.00 per share, a decrease this year of $0.23 per share, and a decrease next year of $0.47 per share.
ProShares Ultra MSCI Emerging Markets Technical Analysis
| Oct 3 | Oct 4 | Oct 7 | Oct 8 | Oct 9 | Oct 10 | Oct 11 | Oct 14 | Oct 15 | Oct 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 03 | 04 | 07 | 08 | 09 | 10 | 11 | 14 | 15 | 16 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||
Kymera Therapeutics Technical Analysis
| Oct 3 | Oct 4 | Oct 7 | Oct 8 | Oct 9 | Oct 10 | Oct 11 | Oct 14 | Oct 15 | Oct 16 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct | ||||||||||
| 03 | 04 | 07 | 08 | 09 | 10 | 11 | 14 | 15 | 16 | |
| Technical Analysis: Buy or Sell? | ||||||||||
| 8-day SMA: | ||||||||||
| 20-day SMA: | ||||||||||
| 50-day SMA: | ||||||||||
| 200-day SMA: | ||||||||||
| 8-day EMA: | ||||||||||
| 20-day EMA: | ||||||||||
| 50-day EMA: | ||||||||||
| 200-day EMA: | ||||||||||
| MACD (12, 26): | ||||||||||
| Relative Strength Index (14 RSI): | ||||||||||
| Bollinger Bands (25): | ||||||||||
| Bollinger Bands (100): | ||||||||||